SEMPRUS BIOSCIENCES AWARDED $1 MILLION U.S. ARMY GRANT TO DEVELOP “ANTI-BIOFILM TRAUMA DEVICES” FOR AMERICAN SOLDIERS IN BATTLE

October 19, 2011

CAMBRIDGE, MA – (October 19, 2011)Semprus BioSciences today announced it has received a $1 million grant from the U.S. Army Telemedicine & Advanced Technology Research Center (TATRC) to develop the world’s first orthopedic devices designed to reduce biofilm formation, the foundation for most bacterial complications associated with medical device implants. Semprus presented its initial findings in a poster session at the recent Advanced Technology Applications for Combat Casualty Care (ATACCC) military trauma conference in Fort Lauderdale, FL.

Semprus BioSciences is a venture-funded biomedical company whose proprietary rationally designed Semprus™ Technology organizes, manages and harnesses water molecules on a medical device surface. This system creates a highly non-fouling performance that significantly reduces attachment of proteins, cells, bacteria and other biological matter. The company’s products are designed to reduce the 56,000 preventable annual U.S. deaths and $11.2 billion cost of infection and thrombus-related complications1 that often arise when medical devices are implanted in the body.

Gunshot wounds, blast injuries and landmine explosions cause the majority of battlefield wounds to American soldiers. Between 60%-70% of soldiers who are wounded suffer from orthopedic injuries, which lead to significant morbidity and failure to return to duty. If a bone fracture becomes infected, the patient requires a prolonged course of treatment that can require multiple surgical procedures, long-term antibiotic care and even amputation. Each year, orthopedic device infections cost the U.S. nearly $2 billion and 11,000 deaths2.

Joseph Wenke, Ph.D., a principal expert on improving outcomes for open fractures at the U.S. Army Institute of Surgical Research (USAISR), is leading this collaborative effort. “I look forward to working with Semprus to help resolve a critical issue affecting our Wounded Warriors,” said Dr. Wenke. “We are hopeful that our collaboration with Semprus will yield new orthopedic products that will greatly reduce complications associated with these injuries, and the costs to treat them.”

Semprus BioSciences Chief Technology Officer Christopher Loose, Ph.D., is coordinating the research and development to bring this novel technology to the clinic on intramedullary nails. According to Dr. Loose, Semprus™ Technology has the potential to improve clinical outcomes for soldiers who suffer from extremity trauma.

“Our goal is to dramatically reduce complication rates in orthopedic devices implanted in our men and women in the Armed Forces,” he said. “We expect our technology to reduce wound complications, amputation and mortality in soldiers with orthopedic injuries.”

Dr. Loose added that the benefits of the technology in development will be particularly relevant to military personnel, including:

  • Long-term antimicrobial activity for the multiple months required for fracture healing, as opposed to “slow release” technologies that utilize a drug reservoir with a limited inherent lifespan (1-2 weeks).
  • Broad spectrum activity against all of the pathogens commonly found on the battlefield, including A. baumannii.
  • Minimal Drug Resistance because these chemistries use non-specific mechanisms to reduce biofilm formation.

“With widespread use across the military in different combat environments, fracture fixation devices are undoubtedly a permanent aspect of battlefield care,” said Semprus BioSciences Chief Executive Officer David L. Lucchino, “and the reduction of associated infections is critical to streamline the treatment process and minimize recovery time.” Lucchino said the Semprus™ Technology can also be applied to other orthopedic devices, including external fixation systems, screws and plates.

The scope of the work performed in this collaborative effort will focus on adapting Semprus™ Technology to orthopedic substrates, including titanium.

BioFlash

Membership Deliverables

MassBio Membership gives you:

Purchasing power-MassBio negotiates a broad-based collection of services on behalf of member companies and passes the savings on to its members. 

Networking and professional development-MassBio organizes and executes numerous conferences, committee meetings, and networking events throughout the year.

MassBio Signature Events-Attend our Investors Forum, Innovator Roundtables, Pharma Days, our Golf Classic Fundraiser, Policy Leadership Breakfast, and many others.

Public policy & Advocacy-As the state's leading advocate for our life science super cluster, we fight for public policy initiatives and tax incentives in Massachusetts and Washington, D.C., that will enable biotechnology companies to do their best work.

Economic development-MassBio provides expert advice and guidance to help companies find suitable locations and resources as they move to and grow in the Bay State. We make Massachusetts a better place for your business.

Visibility/Resources-Members are listed on a searchable directory that includes a profile and link to the company's website. We highlight your company's latest news by posting to our MassBio member news page. In addition, members can post job openings on our website free!

Educational incentives-We promote education, workforce development and lifelong learning through the MassBioEd Foundation. The foundation customizes training programs for companies and educational institutions and promotes science in the classroom through BioTeach. MassBio members receive a discount on courses offered by the foundation.